Metabolomic Profiling and Drug Interaction Characterization Reveal Riboflavin As a Breast Cancer Resistance Protein–Specific Endogenous Biomarker That Demonstrates Prediction of Transporter Activity In VivoYueping Zhang, Hong Shen, Petia Shipkova et al.|Drug Metabolism and Disposition|2023Cited by 15
A Pilot Study To Assess the Suitability of Riboflavin As a Surrogate Marker of Breast Cancer Resistance Protein in Healthy ParticipantsHong Shen, Michael Sinz, Andrew J. Paris et al.|Journal of Pharmacology and Experimental Therapeutics|2024Cited by 15
Evaluation of Encequidar as An Intestinal P-gp and BCRP Specific Inhibitor to Assess the Role of Intestinal P-gp and BCRP in Drug-Drug InteractionsJessica Chu, Hong Shen, Michael Sinz et al.|Pharmaceutical Research|2023Cited by 7